Fig. 3

Ruxolitinib does not affect viral release from resting CD4⁺ T cells. No significant change in HIV-1 viral release was observed in resting CD4⁺ T cell cultures exposed to ingenol-3,20-dibenzoate (Ing DB) or antibodies against CD3 and CD28 (αCD3/28, positive control) in the presence of ruxolitinib (Rx) compared to Ing DB or αCD3/28 alone. Horizontal bars represent geometric mean values within each culture condition. Resting CD4⁺ T cells were obtained from aviremic ART-treated individuals cultured ex vivo (n = 7)